Wistar receives $4.7 million to develop drug against Epstein-Barr virus-related cancers

December 15, 2011

The Wistar Institute today announced that it has signed a funding agreement with the Wellcome Trust, a United Kingdom-based charity, to support the development of a new drug to treat cancers associated with Epstein-Barr virus (EBV). The Seeding Drug Discovery Award of up to $4.7 million will support on-going translational research in the laboratory of Wistar Professor Paul M. Lieberman, Ph.D. If successful, the new therapeutic could be the first to treat EBV-related cancer by attacking the virus as it remains dormant in a patient's cells.

The project is a three-year, multi-stage effort where funding is based on the achievement of defined research milestones, outlined by Lieberman and Troy Messick, Ph.D., a staff scientist in the Lieberman laboratory and co-leader on the project.

"On behalf of The Wistar Institute, I would like to thank the Wellcome Trust for seeing the potential for this project to save countless lives across the globe," said Russel E. Kaufman, M.D., CEO and president of The Wistar Institute. "This effort reflects translational research at its finest by combining a visionary charitable foundation, a promising line of research, and a solid plan for transforming basic science into practical medicine."

Epstein-Barr Virus (EBV) is classified by the World Health Organization as a Class I carcinogen, and it is estimated to cause a small but significant portion of all human cancers. The virus may persist in the human body for decades and cause infected cells to become cancerous. It is estimated that EBV causes nearly 400,000 cases of cancer each year, including Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, gastric carcinoma and certain oral and throat cancers.

According to Lieberman, EBNA1, a protein produced by EBV, is a prime target for therapeutic intervention. The protein acts as the master switch that regulates viral gene activity and guides the ability of EBV to remain dormant in the body.

"EBNA1 is expressed consistently in all EBV-related cancer and is essential for the virus to reproduce," said Lieberman. "Knocking out EBNA1, therefore, could likely eliminate latent Epstein-Barr virus and control the growth of EBV-associated cancer."

Lieberman heads Wistar's Center for Chemical Biology and Translational Medicine, a team of researchers whose mission is to develop promising basic research findings into new therapeutics to fight disease, particularly cancer.

To develop an anti-EBV drug, the researchers began a complex screening process to find a small molecule that could chemically bind to EBNA1 and inhibit its ability to function. They began with a library of 600,000 molecular compounds, eventually narrowing the pool down through a series of tests to a handful of leading candidate molecules that have the most potential to serve as the basis of new anti-EBV drug.

With funds from the Wellcome Trust, the Wistar researchers will further optimize their candidate small molecule inhibitors, with the aim of developing at least one chemical compound into a viable drug candidate. This drug candidate could then be used in clinical trials designed to determine its safety and effectiveness for humans.

"This is an investment in drug discovery, enabling a small team of experts to do the type of translational research typically seen in large drug companies," said Messick. "If successful with the translational research funded by the Wellcome Trust, the program will be in a position to attract a commercial partner to undertake further clinical development."
-end-
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today's Discoveries - Tomorrow's Cures. On the Web at http://www.wistar.org

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. http://www.wellcome.ac.uk

The Wistar Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.